doi: 10.1001/jamainternmed.2015.5868.
Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall Survival: An Analysis of 5 Years of US Food and Drug Administration Approvals
Affiliations
- PMID: 26502403
- DOI: 10.1001/jamainternmed.2015.5868
Item in Clipboard
Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall Survival: An Analysis of 5 Years of US Food and Drug Administration Approvals
JAMA Intern Med.
2015 Dec.
No abstract available
Comment in
-
Balancing Accelerated Approval for Drugs With Accelerated Withdrawal.JAMA Intern Med. 2016 Apr;176(4):566-7. doi: 10.1001/jamainternmed.2016.0351. JAMA Intern Med. 2016. PMID: 27043114 No abstract available.
-
Balancing Accelerated Approval for Drugs With Accelerated Withdrawal--Reply.JAMA Intern Med. 2016 Apr;176(4):567. doi: 10.1001/jamainternmed.2016.0374. JAMA Intern Med. 2016. PMID: 27043117 No abstract available.
-
Demand cancer drugs that truly help patients.Nature. 2018 Apr;556(7700):151. doi: 10.1038/d41586-018-04154-9. Nature. 2018. PMID: 29636577 No abstract available.
Similar articles
-
End points and United States Food and Drug Administration approval of oncology drugs.J Clin Oncol. 2003 Apr 1;21(7):1404-11. doi: 10.1200/JCO.2003.08.072. J Clin Oncol. 2003. PMID: 12663734
-
Ultimate fate of oncology drugs approved by the us food and drug administration without a randomized Trial.J Clin Oncol. 2009 Dec 20;27(36):6243-50. doi: 10.1200/JCO.2009.23.6018. Epub 2009 Oct 13. J Clin Oncol. 2009. PMID: 19826112 Review.
-
Assessing tumor-related signs and symptoms to support cancer drug approval.J Biopharm Stat. 2004 Feb;14(1):5-21. doi: 10.1081/BIP-120028503. J Biopharm Stat. 2004. PMID: 15027497 Review.
-
U.S. Food and Drug Administration anticancer drug approval trends from 2016 to 2018 for lung, colorectal, breast, and prostate cancer.Int J Technol Assess Health Care. 2020;36(1):20-28. doi: 10.1017/S0266462319000813. Epub 2019 Nov 28. Int J Technol Assess Health Care. 2020. PMID: 31775939
-
Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer.JAMA. 2011 Jun 8;305(22):2320-6. doi: 10.1001/jama.2011.769. JAMA. 2011. PMID: 21642684
Cited by
-
Modeling Overall Survival in Patients With Pancreatic Cancer From a Pooled Analysis of Phase II Trials.Cancer Med. 2024 Oct;13(19):e70289. doi: 10.1002/cam4.70289. Cancer Med. 2024. PMID: 39387320 Free PMC article.
-
Estimating the replicability of highly cited clinical research (2004-2018).PLoS One. 2024 Aug 7;19(8):e0307145. doi: 10.1371/journal.pone.0307145. eCollection 2024. PLoS One. 2024. PMID: 39110675 Free PMC article.
-
Bevacizumab-Based Therapies in Malignant Tumors-Real-World Data on Effectiveness, Safety, and Cost.Cancers (Basel). 2024 Jul 19;16(14):2590. doi: 10.3390/cancers16142590. Cancers (Basel). 2024. PMID: 39061228 Free PMC article.
-
An empirical analysis of overall survival in drug approvals by the US FDA (2006-2023).Cancer Med. 2024 Apr;13(8):e7190. doi: 10.1002/cam4.7190. Cancer Med. 2024. PMID: 38659418 Free PMC article.
-
Evaluation of changes in the clinical benefits of oncology drugs over time following reimbursement using the ASCO-VF and the ESMO-MCBS.J Cancer Res Clin Oncol. 2024 Mar 4;150(3):113. doi: 10.1007/s00432-023-05587-0. J Cancer Res Clin Oncol. 2024. PMID: 38436796 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
